Formycon And Bioeq Offer Ranibizumab Update
Partners Set Out Next Steps For Lucentis Biosimilar In US And EU
Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.
You may also be interested in...
Achieving superior stability profiles, leading to additional value propositions for development projects, is the aim of the game for Formycon and Leukocare under a new strategic development agreement.
In an exclusive interview, Samsung Bioepis’ head of clinical research, Il Sun Hong, tells Generics Bulletin how the company managed to put itself at the head of the pack in the chase for biosimilar Eylea (aflibercept); and how the biosimilar can coexist with biosimilars to Lucentis (ranibizumab), which may debut later this year.
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.